Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.60 |
| ▸ | MC4R | P32245 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | CTSH | P09668 | 1/20 | 0.54 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465002 | 1.00 | IL23R (0.60) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL30464993 | 0.98 | IL23R (0.58) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL30464997 | 0.97 | IL23R (0.57) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL30464995 | 0.96 | IL23R (0.61) | IL23RMC4RGHSR | |
| SCHEMBL29814670 | 0.96 | IL23R (0.61) | IL23RMC4RGHSR | |
| SCHEMBL1370998 | 0.96 | IL23R (0.65) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL30464982 | 0.95 | IL23R (0.59) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL30464985 | 0.94 | IL23R (0.58) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL30750449 | 0.93 | IL23R (0.52) | IL23RMC4RCTSLCTSSCTSK | |
| SCHEMBL21146569 | 0.93 | IL23R (0.66) | IL23RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622994-B2 | Therapy for vitiligo | CLINUVEL PHARMACEUTICALS LIMITED (AU) | 2023-04-11 | — | — | US | claimed |
| EP-3573645-B1 | ALPHA-MSH ANALOGUES USED IN THE TREATMENT OF XERODERMA PIGMENTOSUM | VALLAURIX MC S A R L (MC) | 2024-03-13 | — | — | EP | disclosed |
| EP-3030256-B1 | NDP-MSH FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS | CLINUVEL PHARMACEUTICALS LTD (AU) | 2024-01-24 | — | — | EP | disclosed |
| US-11622994-B2 | Therapy for vitiligo | CLINUVEL PHARMACEUTICALS LIMITED (AU) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622994-B2 | Therapy for vitiligo | MC1R, MC3R, MC5R | IL23R 34/4885MC4R 4/4885CTSL 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.